Quentis Therapeutics inks $48 mln Series A
New York City-based Quentis Therapeutics, a biotech company that focuses on treating cancer patients, has raised $48 million in Series A funding. The investors included Versant Ventures, Polaris Partners, AbbVie Ventures, Taiho Pharmaceutical Co. Ltd, Yonghua Capital, Alexandria Venture Investments and New York Ventures, the investment arm of Empire State Development.
28 February 2018•1 min read
